AP adjuvant |
|
Vaxjo ID |
257 |
|
Vaccine Adjuvant Name |
AP adjuvant |
|
Alternative Names |
AddaVax and PolyI:C combined adjuvant |
|
Adjuvant VO ID |
VO_0005744
|
|
Description |
A combination of AddaVax (MF59-like squalene-based oil-in-water nanoemulsion) and PolyI:C (TLR3 agonist). It is designed to improve both humoral and cellular immune responses by combining the properties of both adjuvants. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
AddaVax and PolyI:C combined adjuvant (AP adjuvant) |
|
Structure |
Mixture of: AddaVax: oil-in-water emulsion PolyI:C: synthetic double-stranded RNA analog Not a single molecular entity; physical mixture. |
|
Preparation |
Mixed in a 1:1 (v/v) ratio: AddaVax PolyI:C (50 μg per mouse per dose) |
|
Dosage |
Vaccine: H3 antigen at 3–15 μg per mouse Adjuvant: PolyI:C at 50 μg/mouse, mixed with equal volume of AddaVax |
|
Function |
These findings indicate that AP is a potential novel adjuvant and can be used as a safe and effective adjuvant for MDCK-based influenza inactivated vaccine to induce cellular and antibody protective response. |
|
Safety |
Good safety profile |
| References |
Nian et al., 2021: Nian X, Zhang J, Deng T, Liu J, Gong Z, Lv C, Yao L, Li J, Huang S, Yang X. AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice. AAPS PharmSciTech. 2021; 22(8); 270. [PubMed: 34766215].
|
